Skip to main content
. 2018 Apr 25;7(7):e1448332. doi: 10.1080/2162402X.2018.1448332

Figure 3.

Figure 3.

Intra-tumoral antigen-presenting cells of MMR-proficient LM-CRC express inhibitory ligands. Expression of inhibitory ligands PD-L1, galectin 9 (GAL-9), MHC-II, CD86 and CD80 was measured by flow cytometry. (A) The frequencies of CD19+ B cells, BDCA1+CD19− mDC and CD14+ monocytes (Mono) within CD45+ cells derived from tumors, TFL and blood. Values of individual patients are presented, lines depict medians. (B) Representative histograms of inhibitory ligand stainings and isotype controls on tumor-infiltrating mDC, monocytes and B cells. (C) The frequencies of inhibitory ligand positive cells within tumor-infiltrating B cells, mDC and monocytes in individual patients are presented; lines depict medians. (D) The median fluorescence intensities (MFI) of inhibitory ligands on B cells, mDC and monocytes derived from tumors, TFL and blood of LM-CRC patients. Values of individual patients are shown, and lines depict medians. Differences were analyzed by paired t test or Wilcoxon matched pairs test; *p < 0.05, **p < 0.01, ***p < 0.001.